Recombinant CHO-K1 cells expressing cleaved, mature human Mesothelin (MSLN) gene (GenBank Accession #NM_005823.5) under the control of cytomegalovirus (CMV) promoter. This cell line was generated by limited dilution and isolation of individual clones, which were screened based on MSLN expression to obtain a high-expressing cell line.
Mycoplasma testing: The cell line has been screened to confirm the absence of Mycoplasma species.
Host Species: hamster
Supplied as 2 vials of frozen cells. 2 x 10^6 in 1 ml of 90% FBS, 10% DMSO
Background
Mesothelin (MSLN) is a glycophosphatidylinositol (GPI) linked cell-surface protein that is produced as a ~70 kDa precursor protein and cleaved by Furin protease to generate the ~40 kDa mature form. MSLN is frequently over-expressed in mesothelioma, ovarian, pancreatic, and non-small cell lung cancers, while its expression in normal tissues is restricted to the mesothelial lining. MSLN is a tumor-associated antigen and has been an attractive target for targeted immunotherapy approaches, including drug-conjugated antibodies and chimeric antigen receptor T-cells (CAR-T Cells).
Application
Useful as MSLN-expressing target cells in co-culture assays with MSLN CAR-T cells and for screening other MSLN-binding molecules.
License Disclosure: Visit Biohippobioscience.com/license for the label license and other key information about this product. Troubleshooting Guide: Visit Biohippobioscience.com/cell-line-faq for detailed troubleshooting instructions. For all further questions, please email [email protected]. Warning: Avoid freeze/thaw cycles.
Storage Stability
Cells will arrive upon dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage.
Reference
1. Asgarov, K., et al. (2017). A new anti-mesothelin antibody targets selectively the membrane-associated form. MAbs, 9(3): 567-577. https://doi.org/10.1080/19420862.2017.1288770. 2. Ye, L., et al. (2019). Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors in vivo. Experimental and Therapeutic Medicine, 17: 739-747. https://doi.org/10.3892/etm.2018.7015